{"id":"NCT00358436","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2006-07-31","resultsPosted":"2012-11-01","lastUpdate":"2017-01-04"},"enrollment":804,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"Aclidinium bromide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Aclidinium 200 μg once-daily","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.","primaryOutcome":{"measure":"Trough FEV1 (L) at 28 Weeks on Treatment","timeFrame":"28 weeks","effectByArm":[{"arm":"Aclidinium Bromide 200 μg Once-daily","deltaMin":1.22,"sd":0.008},{"arm":"Placebo","deltaMin":1.162,"sd":0.014}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":120,"countries":["United States","Argentina","Australia","Canada","Mexico","New Zealand","South Africa"]},"refs":{"pmids":["21518460"],"seeAlso":["http://www.almirall.com/webcorp2/cda/ImD_04_02.jsp"]},"adverseEventsSummary":{"seriousAny":{"events":62,"n":600},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Back pain","Diarrhoea"]}}